The clinical efficacy and tolerability of intrapleural sclerotherapy using a binary catalyst system teraftal + ascorbic acid and intrapleural immunotherapy with allogeneic LAK cells and low-dose recombinant interleukin-2 (roncoleukin) in patients with tumor (metastatic) pleurisy at various chemoresistant malignancies was studied. The results showed that this treatment is highly effective (objective response when sclerotherapy was 82%), and immunotherapy (IL-2/ LAK 92.4% and IL-2 80%), relatively rarely give recurrences and satisfactorily tolerated patients.
分享
引用
